

B: Biomaterials and Membranes

Interactions of Cationic Diruthenium Trithiolato Complexes With Phospholipid Membranes Studied by NMR Spectroscopy

Hedvika Primasová, Martina Vermathen, and Julien Furrer

J. Phys. Chem. B, **Just Accepted Manuscript** • DOI: 10.1021/acs.jpcc.0c05133 • Publication Date (Web): 15 Sep 2020Downloaded from pubs.acs.org on September 17, 2020

Just Accepted

“Just Accepted” manuscripts have been peer-reviewed and accepted for publication. They are posted online prior to technical editing, formatting for publication and author proofing. The American Chemical Society provides “Just Accepted” as a service to the research community to expedite the dissemination of scientific material as soon as possible after acceptance. “Just Accepted” manuscripts appear in full in PDF format accompanied by an HTML abstract. “Just Accepted” manuscripts have been fully peer reviewed, but should not be considered the official version of record. They are citable by the Digital Object Identifier (DOI®). “Just Accepted” is an optional service offered to authors. Therefore, the “Just Accepted” Web site may not include all articles that will be published in the journal. After a manuscript is technically edited and formatted, it will be removed from the “Just Accepted” Web site and published as an ASAP article. Note that technical editing may introduce minor changes to the manuscript text and/or graphics which could affect content, and all legal disclaimers and ethical guidelines that apply to the journal pertain. ACS cannot be held responsible for errors or consequences arising from the use of information contained in these “Just Accepted” manuscripts.

1
2
3
4
5
6
7 Interactions of Cationic Diruthenium Trithiolato
8
9
10
11 Complexes with Phospholipid Membranes Studied
12
13
14
15 by NMR Spectroscopy
16
17
18
19

20 *Hedvika Primasová **, *Martina Vermathen ** and *Julien Furrer **
21
22
23
24

25 Department of Chemistry and Biochemistry, University of Bern, Freiestrasse 3, CH-3012
26
27

28 Bern, Switzerland
29
30
31
32

33 KEYWORDS ruthenium complex, hydrophobic cation, interaction, membrane model,
34
35
36 liposome, micelle, phospholipid, nuclear magnetic resonance
37
38
39
40

41 ABSTRACT. To apprehend the possible mechanisms involved in the cellular uptake and
42
43
44 the membrane interactions of cytotoxic dinuclear *p*-cymene trithiolato ruthenium(II)
45
46
47 complexes, the interactions of the complexes $[(\eta^6\text{-}p\text{-MeC}_6\text{H}_4\text{Pr}')_2\text{Ru}_2(\text{R}^1)_2(\text{R}^2)]^+$ ($\text{R}^1 = \text{R}^2$
48
49 = $\text{SC}_6\text{H}_4\text{-}m\text{-Pr}^i$:1; $\text{R}^1 = \text{SC}_6\text{H}_4\text{-}p\text{-OMe}$, $\text{R}^2 = \text{SC}_6\text{H}_4\text{-}p\text{-OH}$:2; $\text{R}^1 = \text{SCH}_2\text{C}_6\text{H}_4\text{-}p\text{-OMe}$, R^2
50
51 = $\text{SC}_6\text{H}_4\text{-}p\text{-OH}$:3) with 1,2-dioleoyl-*sn*-glycero-3-phosphocholine (DOPC) vesicles and
52
53
54
55
56
57
58
59
60

1
2
3
4 1,2-dihexanoyl-*sn*-glycero-3-phosphocholine (DHPC) micelles were studied using
5
6
7 nuclear magnetic resonance (NMR) spectroscopy. ^1H , NOE, DOSY, and T_1 and T_2
8
9
10 relaxation data provided information on interactions between the complexes and the
11
12
13 model membranes and on the submolecular localization of the complexes at the
14
15
16 membrane interface. The results suggest that (a) interaction takes place without new
17
18
19 covalent adduct formation, (b) the cationic diruthenium complexes interact with DOPC
20
21
22 head groups most likely involving electrostatic interactions while remaining structurally
23
24
25 unchanged, (c) the changes indicating interactions are more pronounced for the most
26
27
28 lipophilic complex **1**, (d) the diruthenium complexes remain at the exterior vesicle surface
29
30
31 and unlikely insert between the phospholipid chains. The complexes also interact with
32
33
34 micellar/free DHPC and seem to induce micellization or aggregation in sub-CMC
35
36
37 solutions. Our study suggests a high affinity of the Ru complexes for the membrane
38
39
40 surface that likely plays a key role in cellular uptake and possibly also in redistribution to
41
42
43
44
45
46
47
48
49 mitochondria.
50
51
52
53
54
55
56
57
58
59
60

1
2
3 INTRODUCTION In recent years, our group has focused on the development of cationic
4
5
6
7 dinuclear thiolato-bridged arene Ruthenium(II) complexes (in the following named
8
9
10 *diruthenium complexes*) as anti-cancer and antiparasite agents.¹⁻⁵ The trithiolato
11
12
13
14 diruthenium complexes of the general formula $[(\eta^6\text{-arene})_2\text{Ru}_2(\mu\text{-SR})_3]^+$ and $[(\eta^6\text{-}$
15
16
17 $\text{arene})_2\text{Ru}_2(\mu\text{-SR}_1)_2(\mu\text{-SR}_2)]^+$ are highly cytotoxic against ovarian cancer cell lines A2780
18
19
20 and their cis-Pt resistant analogs A2780cisR.¹ The most active derivative $[(\eta^6\text{-}p$
21
22
23 $\text{MeC}_6\text{H}_4\text{Pr}')_2\text{Ru}_2(\mu_2\text{-S-}p\text{-C}_6\text{H}_4\text{Bu}')_3]\text{Cl}$, termed diruthenium-1 or DiRu-1, has an IC_{50} value
24
25
26
27 of 30 nM in both cell lines. It has also shown *in vivo* activity as it significantly prolonged
28
29
30 the survival of tumor-bearing mice.⁶ DiRu-1 is among the most cytotoxic Ru complexes
31
32
33 reported to date.¹
34
35
36
37

38 The trithiolato diruthenium complexes are stable under physiological conditions. While
39
40
41 the exact mechanism of action is not completely clear yet, it has been shown that they
42
43
44 are able to catalyze glutathione (GSH) and cysteine (Cys) oxidation and to induce reactive
45
46
47 oxygen species (ROS) burst and DNA lesion formation, which can all lead to apoptosis
48
49
50 and cell cycle arrest in treated cancer cells.⁶⁻⁹ Recently, it has been shown using ICP-MS
51
52
53 that treatment of cancer cells with other very similar diruthenium complexes results in a
54
55
56
57
58
59
60

1
2
3 specific accumulation of Ru in mitochondria.⁵ Likewise, Ru was found in mitochondria of
4
5
6
7 *T. gondii* treated with other again comparable diruthenium complexes.¹⁰ Additionally,
8
9
10 structural changes in mitochondria were observed by TEM in *N. caninum* treated with
11
12
13 these complexes.⁵ However, the exact location of Ru within mitochondria is not known
14
15
16
17 yet.^{5,10}
18
19
20

21 In order to enter cells and subsequently cell-organelles, the drug needs to cross
22
23 the plasma membrane, which takes place mostly via passive diffusion, with the help of
24
25
26
27 transporters, or via endocytosis. Whether the drug will pass via passive diffusion depends
28
29
30 on factors such as lipophilicity, ability to form H bonds, charge and size of the drug, pH of
31
32
33 the system, and membrane potential.^{11,12} Hydrophilic molecules usually are not able to
34
35
36
37
38 cross the plasma membrane without the help of membrane transporters, and charged
39
40
41 molecules encounter the problem of crossing the hydrophobic core of a bilayer.¹³
42
43
44 Lipophilic cations, on the other hand, are known to be able to passively diffuse through
45
46
47
48 membranes.^{14,15}
49
50
51

52 If an organometallic compound does not act as a prodrug, like CO-releasing
53
54
55 organometallic compounds *in vivo*,¹⁶ one of the most important prerequisites for
56
57
58
59
60

1
2
3 preventing side effects and general toxicity is that the compound enters cells virtually
4
5
6 intact, which requires that no or only weak interactions, such as hydrogen bonds, between
7
8
9
10 the compound and cell membranes exist. The chemical nature of the surrounding ligands
11
12
13 strongly influences the propensity of the metal to be oxidized or reduced and triggers the
14
15
16 potential interactions with the cell membranes. The factors influencing the toxicity and
17
18
19 efficacy of diruthenium complexes are lipophilicity and Hammett coefficient of
20
21
22 the aromatic thiol.^{1,17} For instance, the complexes having Hammett constants in the range
23
24
25 of -0.2 to 0 and partition coefficients between 3.0 and 4.0 are those showing the lowest
26
27
28
29
30
31 IC_{50} values.¹⁷

32
33
34
35 As biological membranes are structurally and composition-wise complex, simplified
36
37
38 artificial model membranes are often studied. There are three model systems commonly
39
40
41 used – planar lipid monolayers, supported bilayers and liposomes.^{18,19} Liposomes are
42
43
44 spherical phospholipid vesicles containing an aqueous compartment. This model is
45
46
47 suitable for studies of drug membrane permeability.²⁰ Additionally to the already
48
49
50 mentioned models, micelles can be used as a simple model of lipid membranes when
51
52
53
54
55 investigating interactions.²¹ Compared to liposomes, micelles are very dynamic species
56
57
58
59
60

1
2
3 coexisting with the free form of their components in solution.²² Micelles are easy to
4
5
6
7 prepare, and nuclear magnetic resonance (NMR) spectra of micellar solutions show
8
9
10 narrower linewidths as compared to phospholipid liposome suspensions. Although
11
12
13 micelles have some limitations due to their monolayered structure, their enhanced
14
15
16 dynamics may offer important complementary information on potential sites of
17
18
19 interactions between the micellar amphiphiles and the drug molecules.
20
21
22
23

24 NMR spectroscopy is a technique that offers numerous possibilities to study
25
26
27 interactions between lipid model membranes and drugs. It allows obtaining information
28
29
30 on diffusion rates and therefrom particle sizes, changes in molecular surroundings,
31
32
33 proximity between two species, and kinetics like relaxation or exchange processes. Using
34
35
36
37
38 NMR spectroscopy, the location of a guest molecule at the vesicle or micelle interface,
39
40
41 aggregation, encapsulation and other aspects of drug-membrane interactions can be
42
43
44
45 studied.^{23–32}
46
47
48

49 This study is aiming to provide an insight into the interactions of diruthenium complexes
50
51
52 with cell membranes. For this purpose, three representative complexes $[(\eta^6\text{-}p\text{-}$
53
54
55 $\text{MeC}_6\text{H}_4\text{Pr}^\wedge)_2\text{Ru}_2(\text{R}_1)_2(\text{R}_2)]^+$ with different degrees of lipophilicity and in vitro cytotoxicity
56
57
58
59
60

1
2
3
4 (R_{1,2} = SC₆H₄-*o*-*i*Pr: **1**; R₁ = SC₆H₄-*p*-OMe; R₂ = SC₆H₄-*p*-OH : **2**; R₁ = SCH₂C₆H₄-OMe;
5
6
7 R₂ = SC₆H₄-*p*-OH : **3**) were selected (Figure 1) and their interactions towards the
8
9
10 membrane models 2-dioleoyl-*sn*-glycero-3-phosphocholine (DOPC) vesicles and 1,2-
11
12 dihexanoyl-*sn*-glycero-3-phosphocholine (DHPC) micelles were studied with NMR
13
14 spectroscopy as main tool. Even though, DHPC has rather detergent than lipid-like
15
16
17 properties, it will be referred to as (short chain) phospholipid here to underline its close
18
19
20
21 chemical relationship as a phosphatidylcholine with DOPC.
22
23
24
25
26
27




Figure 1. Structures of the three diruthenium complexes (**1-3**) investigated in this work.

EXPERIMENTAL

Materials: The diruthenium complexes **1-3** were synthesized according to published methods.^{3,33,34} All chemicals were used as received. 1,2-dioleoyl-*sn*-glycero-3-

1
2
3 phosphocholine (DOPC) and 1,2-dihexanoyl-*sn*-glycero-3-phosphocholine (DHPC) were
4
5
6
7 obtained from Avanti Polar Lipids Inc. KH_2PO_4 and Na_2HPO_4 were purchased from Sigma
8
9
10 Aldrich. Deuterated solvents were obtained from Cambridge Isotope Laboratories, Inc,
11
12
13
14 PrCl_3 from Aldrich Chem. Co.
15
16

17 Phosphate buffered saline (PBS) solution was prepared from aliquots of 50 mM KH_2PO_4
18
19
20 and 50 mM Na_2HPO_4 solutions containing 0.9% NaCl in D_2O to reach a pD corresponding
21
22
23
24 to measured pH of 7.0. Unless otherwise specified, the interaction experiments were
25
26
27 performed in deuterated PBS/dDMSO 4:1 (pD^{mixture} corresponding to measured pH of 7.7)
28
29
30
31 to allow dissolution of the sparingly soluble diruthenium complexes 1-3.
32
33

34 **Preparation of liposomes:** DOPC vesicles were freshly prepared before every new set
35
36
37 of experiments. DOPC was dissolved in chloroform in a glass vial, and the solvent was
38
39
40
41 subsequently evaporated upon an argon stream to leave a uniform lipid film on the walls.
42
43
44
45 The residual solvent was removed in vacuo. The resulting homogeneous film was
46
47
48 hydrated with PBS by vortexing to obtain a 12.5 mM DOPC suspension. The suspension
49
50
51
52 was subsequently sonicated for 30 min at room temperature in the center of an ultrasonic
53
54
55
56
57
58
59
60

1
2
3 bath. When the DOPC vesicles were investigated alone, dDMSO was added to
4
5
6
7 the prepared vesicles to obtain a final DOPC concentration of 10 mM.
8
9

10 **Preparation of micelles:** Critical micelle concentration (CMC) of DHPC in PBS/dDMSO
11
12 4:1 and at 310 K was determined using 2D ^1H Diffusion Ordered Spectroscopy (DOSY)
13
14 NMR.^{35,36} DOSY spectra of DHPC solutions of incremented concentrations were
15
16
17 recorded, and the resulting diffusion coefficients obtained from processed DOSY pseudo-
18
19
20 2D spectra were plotted against the log of the concentration. The CMC (25 mM, Figures
21
22
23 S1-3) was estimated to lie at the intersection of two linear regions.³⁵ Subsequently,
24
25
26
27 28 mM DHPC solution in PBS/dDMSO 4:1 was prepared.
28
29
30
31
32
33

34
35 **Mixtures of diruthenium complexes with phospholipids:** The diruthenium complexes **1**,
36
37
38 **2**, and **3** were dissolved in dDMSO to give 5 mM stock solutions. Note that the complexes
39
40
41 are stable in dDMSO over a long period.^{1,9} In order to investigate the interactions with
42
43
44 lipid membrane models, 20 μL of each complex solution in dDMSO was gently mixed with
45
46
47
48 80 μL of a suspension of lipid vesicles or micelles in deuterated PBS, respectively.
49
50
51
52 Mixtures of 1 mM complex and 10 mM DOPC vesicles or 28 mM DHPC, respectively,
53
54
55
56 resulted. When the diruthenium complexes were investigated alone, pure PBS was added
57
58
59
60

1
2
3 to reach 1 mM solutions. For NOE NMR experiments (see below), 800 μ L of the sample
4
5
6
7 were prepared.
8
9

10 An alternative preparation method involving hydration of the film formed by the complex
11
12 and the lipid (co-dissolved in organic solvent) after solvent removal in PBS and
13
14 subsequent addition of a corresponding amount of dDMSO was used to test the effect of
15
16
17
18
19
20
21 co-dissolution in comparison to the addition of **1-3** to preformed vesicles.³⁷ For this,
22
23
24 DOPC and each diruthenium complex were dissolved in chloroform, which subsequently
25
26
27 was evaporated and the flask with the resulting film dried in vacuo as described above.
28
29
30
31 PBS was added to the film, the flask vortexed followed by 30 min sonication at room
32
33
34
35 temperature to give a suspension containing the diruthenium complex and DOPC
36
37
38 vesicles. After sonication, dDMSO was added. The resulting concentrations of the
39
40
41 diruthenium complex and DOPC in PBS/dDMSO 4:1 were 1 mM and 10 mM,
42
43
44
45 respectively.
46
47
48

49 **NMR spectroscopy:** ^1H - and ^{31}P -spectra, T_1 and T_2 relaxation measurements, and
50
51
52 DOSY spectra were recorded on a Bruker Avance II NMR spectrometer operating at a
53
54
55
56 nominal ^1H frequency of 500.13 Hz. The spectrometer is equipped with a triple resonance
57
58
59
60

1
2
3
4 (1H, 13C, 31P) 1.7 mm microprobehead with additional z-gradients. 1D NOE and spectra
5
6
7 needed for the characterization of the complexes (13C, COSY, HSQC, HMBC) were
8
9
10 recorded on a Bruker Avance III spectrometer operating at 400.13 MHz equipped with a
11
12
13 5 mm ATM BBFO SmartProbe®. All NMR spectra were recorded at a regulated
14
15
16 temperature of 310 K. Processing and analysis were performed using TopSpin 3.5-6
17
18
19 (Bruker). For DOSY, T₁, and T₂ measurements, Dynamics Center 2.4.2 (Bruker) was used
20
21
22
23
24 for data fitting.
25
26
27

28 *1D 1H and 31P NMR spectroscopy:* 1D 1H NMR spectra were recorded using the *zgpr30*
29
30
31 (Bruker) pulse sequence for presaturation of the residual water resonance. 1D 31P NMR
32
33
34 spectra were obtained using the *zgpg* sequence (Bruker) with broadband 1H decoupling.
35
36
37
38 The diruthenium complexes were mixed with phospholipid vesicles or micelles just before
39
40
41 measurements. For the 1H NMR spectra, the relaxation delay was set to 1 s and the
42
43
44 spectral width to 7352.9 Hz. The irradiation frequency was set individually to the center
45
46
47 of the residual water peak (at approximately 4.7 ppm). Unless otherwise stated, the
48
49
50 acquisition time was 1.11 s, 128-256 scans were recorded, and processing involved line
51
52
53 broadening of 2 Hz, Fourier transformation, phase correction, and automatic baseline
54
55
56
57
58
59
60

1
2
3 correction. ^{31}P spectra were recorded with 32 scans, a spectral width of 40760.87 Hz, 32768
4
5
6 data points, an acquisition time of 0.402 s, and a relaxation delay of 2 s unless otherwise specified.
7
8

9 *NOE spectroscopy:* 1D NOE spectra were recorded using a modified pulse program
10
11
12 *1dnoesy* derived³⁸ from the standard *selnogp* pulse program (Bruker) with the relaxation
13
14
15 delay set to 1 s, the acquisition time to 511 ms and the spectral width to 8012.8 Hz. 2048
16
17
18 scans were recorded. The mixing time was set to 100 ms to minimize the effects of spin
19
20
21 diffusion. The N-methyl and the $(\text{CH}_2)_n$ resonances of the phospholipid chain and one
22
23
24 resonance of the aromatic thiol of the diruthenium complex were irradiated in separate
25
26
27 experiments to obtain information on the possible location of the complex within
28
29
30 the membrane. The frequencies irradiated are indicated in the relevant spectra (Figures
31
32
33
34 2 and S4-6).
35
36
37
38
39

40 *Diffusion ordered spectroscopy:* 2D ^1H DOSY experiments were performed using a
41
42
43 stimulated echo bipolar gradient pulse sequence *ledbpcpgp2scpr* (Bruker) with
44
45
46 longitudinal Eddy current delay, 2 spoil gradients and presaturation of the water
47
48
49 resonance.³⁹ The diffusion time was set to 80 ms, and the relaxation delay to 1 s.
50
51
52
53
54 The gradient strength was linearly varied (2-98%) to reach optimal signal attenuation. At
55
56
57
58
59
60

1
2
3 each gradient strength, 128 scans were recorded in 0.68 s acquisition time. The gradient
4
5
6 strength of our probehead is 5.35 G/cmA. Typically, the gradient pulse length was set to
7
8
9 2-4.5 ms, and the diffusion list contained 24 values in the range of 2-98% of the maximum
10
11
12 gradient strength. All single spectra from the DOSY experiments (series of 1D spectra)
13
14
15 were processed with exponential multiplication applying a line broadening factor of 3 Hz
16
17
18 prior to fitting in Dynamics Center. The examples of fitting plots for DOPC and DHPC can
19
20
21 be found in SI (Figures S7-8), the program was used on selected peak regions excluding
22
23
24 HDO and DMSO. The diffusion coefficient D was obtained from fitting using the Stejskal-
25
26
27 Tanner equation (1)⁴⁰ where I is the signal intensity, I_0 the respective signal intensity at
28
29
30 zero gradient, γ the gyromagnetic ratio of ^1H , g the gradient strength, δ the gradient length
31
32
33 and Δ the delay between dephasing and rephasing gradients.
34
35
36
37
38
39
40

$$I = I_0 \exp \left[\gamma^2 g^2 \delta^2 \left(\Delta - \frac{\delta}{3} \right) D \right] \quad (1)$$

41
42
43
44
45
46 The hydrodynamic radius of DHPC micelles was estimated from DOSY NMR results
47
48
49 according to the Stokes-Einstein equation (2) where D is the diffusion constant, k the
50
51
52 Boltzmann constant,
53
54
55
56
57
58
59
60

$$D = \frac{kT}{6\pi\eta R} \quad (2)$$

1
2
3
4
5
6 T the temperature, η the viscosity of the medium, and R the radius of the particle under
7
8
9 the assumption that DHPC micelles have an approximately spherical shape. Obstruction
10
11
12 effects were not included in the calculation. The viscosity of the mixtures was determined
13
14
15
16 experimentally using a rotary rheometer (see “Dynamic light scattering” below).
17
18
19

20 *Relaxation time measurements:* The inversion recovery experiment employing the
21
22
23 standard *t1irprf1* (Bruker) sequence with presaturation of the water resonance was used
24
25
26 to determine the longitudinal relaxation time T_1 . Depending on the sample, (diruthenium
27
28
29 complexes, phospholipids alone, or a mixture), the relaxation delay was set to 4-10 s with
30
31
32
33
34 variable interpulse delay lists containing 16-18 increments in the range of 0.001-9 s, with
35
36
37
38 32-128 scans for each delay value.
39
40

41 Transverse relaxation times T_2 were measured using the Carr-Purcell-Meiboom-Gill
42
43
44 (CPMG) sequence^{41,42} *cpmgpr* (Bruker) with presaturation of the water resonance. The
45
46
47 relaxation delay was set to 10 s. The spin-echo delay was incremented with 19 values in
48
49
50
51 the range of 8 – 3000 ms suitable for both the ruthenium complexes and the lipids.
52
53
54
55 Depending on the sample, the number of scans was set to 32 or 64 for each increment.
56
57
58
59
60

1
2
3
4 *Lanthanide shift experiments:* The lanthanide shift experiments were performed with
5
6
7 complex **1**, the most soluble among the three diruthenium complexes, by adding
8
9
10 praseodymium (III) chloride PrCl_3 (0.05 mM; 0.1 mM; 1 mM; 5 mM; 10 mM) in a mixture
11
12
13 $\text{D}_2\text{O}/\text{dDMSO}$ (1:4), respectively, to induce broadening and shift of lipid resonances from
14
15
16 the outer layer to distinguish the vesicle exterior surface from interior.⁴³ D_2O was used
17
18
19 instead of PBS to improve solubility. Using the optimal concentration (with respect to
20
21
22 induced shift and resulting lineshapes) of PrCl_3 at 1 mM, ^1H and ^{31}P spectra of DOPC
23
24
25 vesicles in $\text{D}_2\text{O}/\text{dDMSO}$ in the presence of **1** (1 mM) and the lanthanide shift reagent were
26
27
28 recorded. ^{31}P spectra were recorded using the following acquisition parameters: 6144
29
30
31 scans, spectral width of 40760.87 Hz, 8192 data points, acquisition time of 0.10 s, and
32
33
34 relaxation delay of 1 s. ^1H spectra were recorded with 256 scans, spectral width of
35
36
37 7352.94 Hz, 16384 data points, acquisition time of 1.11 s, and relaxation delay of 1 s.
38
39
40
41
42
43
44

45 **Dynamic light scattering:** Dynamic light scattering (DLS) was used to estimate the
46
47
48 hydrodynamic radius in the case of DOPC vesicles. DLS measurements were performed
49
50
51 with the Anton Paar Litesizer 500, using acrylic cuvettes (1 cm path length) and a 660 nm
52
53
54 laser in backscattering mode with 60 runs (time per run 10 s). Data were processed using
55
56
57
58
59
60

1
2
3 the Kalliope 2.8.3 software. For both methods, DOSY NMR and DLS, the viscosity of
4
5
6
7 solutions and suspensions, respectively, was determined using the rotary rheometer
8
9
10 Anton Paar MCR 92. NMR, DLS, and viscosity measurements were all performed at a
11
12
13 regulated temperature of 310 K.
14
15

16
17 **Mass spectrometry:** Electron spray ionization mass spectra of mixtures were recorded
18
19
20 in positive mode using an LTQ Orbitrap XL spectrometer with nano ESI (Thermo).
21
22
23
24
25
26

27 28 RESULTS AND DISCUSSION 29

30
31
32 **Characterization of the diruthenium complexes:** In Table 1, the calculated log P values
33
34
35 for the different thiol ligands of complexes 1-3 are given, indicating their lipophilicity. 1 is
36
37
38 the most lipophilic of the three complexes, and is, *in vitro*, one order more cytotoxic in
39
40 terms of IC_{50} compared to 3.^{3,33} This correlation between lipophilicity and cytotoxicity was
41
42
43 to some extent observed and reported for other complexes of this family against
44
45
46
47
48
49
50 parasites^{5,10} and against cancer cells: the sum of the calculated log P values for the thiol
51
52
53
54
55
56
57
58
59
60

ligands of the most cytotoxic complexes range between 9 and 13.⁴⁴ The lipophilicity can be expected to play a role in interactions with biological membranes.^{11,45}

Table 1. log *P* values of the different thiol ligands (HS-R), the sum of the individual values, and cytotoxicities of the complexes in terms of IC₅₀ values against A2780 cell line and its cisplatin-resistant variant (cisR).^{3,33} The log *P* values have been calculated using ChemDraw 19.0.

	R₁	log <i>P</i>	R₂	log <i>P</i>	Σ	IC₅₀ [μM]
1	SC ₆ H ₄ - <i>o</i> -Pr	3.96	SC ₆ H ₄ - <i>o</i> -Pr	3.96	11.88	A2780: 0.030 ± 0.001 A2780cisR: 0.031 ± 0.001
2	SC ₆ H ₄ - <i>p</i> - OMe	2.54	SC ₆ H ₄ - <i>p</i> - OH	1.87	6.95	-
3	SCH ₂ C ₆ H ₄ - <i>p</i> -OMe	2.33	SC ₆ H ₄ - <i>p</i> - OH	1.87	6.53	A2780: 0.32 ± 0.08 A2780cisR: 0.109 ± 0.03

The use of DMSO as a co-solvent was unavoidable for the three complexes as their solubility in pure 50 mM PBS is too low for the envisaged NMR studies. Out of the three complexes, **1** was the easiest to dissolve, followed by **2**. This ease of dissolution for **1** was unexpected, since it is by far the most lipophilic among the three complexes. The different counterion present with **1** and **2** on the one hand (Cl⁻) and with **3** (BF₄⁻), on the

1
2
3 other hand, may have an influence on their solubility in mixtures PBS/DMSO, but this was
4
5
6
7 not further investigated.
8
9

10 **Characterization of the model membrane systems:** Above CMC, micelles, and free
11
12 phospholipid coexist, and their ratio depends on the total concentration of
13
14 the phospholipid. From the diffusion coefficient D of free DHPC in solution below CMC
15
16 and the average D at a concentration above CMC used for the interaction experiments
17
18 (28 mM), D of micelles was calculated to be $3.16 \cdot 10^{-11}$ m²/s using relation (3)^{46,47}.
19
20
21
22
23
24
25
26
27

28 Assuming that only micellar and free phospholipid species are present, the following
29
30 relation (3) is valid where D^{tot} is the diffusion coefficient for the 28 mM DHPC solution,
31
32 D^{free} for the solution of 10 mM DHPC containing only free species, D^m is the diffusion
33
34 coefficient of the micelles to be determined, and c^{tot} and c^{free} , respectively, are the
35
36 corresponding concentrations.
37
38
39
40
41
42
43
44

$$D^{tot} = D^m \frac{(c^{tot} - c^{free})}{c^{tot}} + D^{free} \frac{c^{free}}{c^{tot}} \quad (3)$$

45
46
47
48
49 The calculated hydrodynamic radius of DHPC micelle is then 4.66 nm. The value is higher
50
51 compared to the values commonly reported for DHPC micelles prepared in water or
52
53
54
55
56
57
58
59
60

1
2
3 aqueous buffers.^{46,48,49} It has been reported that solvents can have an influence on CMC,
4
5
6 micelle size or size of vesicles.⁵⁰⁻⁵² In our case, the medium contains 20% DMSO and
7
8
9
10 D₂O instead of H₂O, which both may contribute to the size deviation.

11
12
13
14 DOPC liposomes were characterized using DLS. For a 10 mM suspension of DOPC
15
16
17 vesicles in PBS/DMSO (D₂O), an average hydrodynamic radius of 83 nm was found with
18
19
20
21 a polydispersity index (PDI) of 27.5% from number weighted distributions (Figure S9).

22 23 24 **Interaction studies:**

25
26
27
28 **1D NMR:** For the interaction studies, 1D ¹H NMR spectra of the pure components were
29
30
31 first recorded, and subsequently 1D ¹H NMR spectra of the mixtures. Whenever
32
33
34 necessary, 2D NMR spectra were acquired for completing/supporting the attribution of
35
36
37
38 the proton resonances.

39
40
41
42 **Single components:** The chemical shifts of the different protons of the individual
43
44
45 components (diruthenium complexes **1-3**, DHPC and DOPC) were in agreement with
46
47
48 literature data, the slight differences being due to the different solvents used (Figures
49
50
51
52 S10-11 and Tables S1-3).^{3,33,53,54}

1
2
3
4 *Mixtures:* (i) Diruthenium complexes: Resonance broadening and small shift changes
5
6
7 were observed in the regions containing the protons of the thiol ligand and *p*-cymene for
8
9
10 all three diruthenium complexes upon addition of DOPC liposomes, suggesting
11
12
13 the existence of weak non-covalent interactions (Figures S12-14 and Tables S1-3). If
14
15
16 covalent bonds had been formed between **1-3** and phospholipid, more pronounced
17
18
19 changes in chemical shift would have been expected. The absence of covalent bonds
20
21
22 between **1-3** and DOPC, as well as the integrity of the complexes, was additionally
23
24
25 confirmed by ESI-MS (Figures S15-17).
26
27
28
29
30

31 The linewidth of NMR resonances is proportional to the transverse relaxation rate $R_2 =$
32
33
34 $1/T_2$, which itself is proportional to the molecular mass or inversely proportional to the
35
36
37 dynamic – given by the correlation time τ_c - of the molecule investigated. Thus, when a
38
39
40 diruthenium complex interacts with the large DOPC vesicles, it acquires the slow dynamic
41
42
43 of the latter, which in turn results in line broadening.
44
45
46
47
48

49 Mixed with DHPC (28 mM) micellar solution, **1-3** showed similar slight shift changes of
50
51
52 several proton resonances (Figures S18-20 and Tables S1-3), but unlike what was
53
54
55 observed with DOPC, no or a very small line broadening of the resonances of **1-3**
56
57
58
59
60

1
2
3 resulted, which is in line with the lower molecular mass of DHPC micelles compared to
4
5
6
7 DOPC vesicles. Indeed, when a diruthenium complex interacts with the small DHPC
8
9
10 micelles, the overall mass of the system (DHPC:complex) is not drastically changed,
11
12
13
14 which in turn does not significantly affect the broadening of the resonances.
15
16

17 Furthermore, it was noticed that DOPC (and to a smaller extent also DHPC) helped the
18
19
20 dissolution of the otherwise sparingly soluble **3**.
21
22

23
24 (ii) DOPC: No changes in the chemical shift or linewidths were observed for the DOPC
25
26
27 signals in the presence of **1-3**, as shown for the presence of complex **1** in Figure S12 b
28
29
30
31 and c.
32
33

34
35 (iii) DHPC: No substantial changes in the shift or linewidths were observed in the
36
37
38 presence of **1-3**. Like DOPC, the resonances of DHPC were not affected upon the
39
40
41 addition of the three diruthenium complexes, which can also be ascribed to the high molar
42
43
44 ratio DHPC:complex (28:1).
45
46

47
48
49 ³¹P NMR: No changes were observed in the ³¹P NMR spectra when **1-3** were added to
50
51
52 DHPC micelles (Figure S21). In the case of DOPC, the ³¹P phosphocholine resonance
53
54
55 overlapped with the intense phosphate resonance of the buffer and was therefore hard to
56
57
58
59
60

1
2
3 evaluate. However, in pure D₂O, the phosphocholine resonance of DOPC vesicles – like
4
5
6
7 the one of DHPC micelles - did not exhibit changes in the presence of the diruthenium
8
9
10 complex **1**, either (see “*Lanthanide shift experiments*”).
11
12

13
14 **NOE:** NOE experiments are long known to afford 1D difference spectra or 2D chemical
15
16
17 shift correlation maps in which through-space connectivities can be traced out.^{55,56} We
18
19
20 therefore used NOE experiments to obtain information on the location of the complexes
21
22
23 at the interface of the phospholipid vesicles or micelles. In our study, selective 1D NOE
24
25
26
27 experiments were applied to allow for satisfactory S/N given the limited solubility of **1-3**.
28
29
30
31 Upon addition of **1**, when irradiating the N-methyl protons of DOPC at 3.33 ppm, apart
32
33
34 from intramolecular NOEs, and NOE at 1.6 ppm, which belongs to the methyl group of *p*-
35
36
37 cymene was observed (proton H in Figure 2b). As the same negative NOE was observed
38
39
40 upon the addition of **2** (Figure S4), which does not possess an isopropyl group on the
41
42
43 thiol ligand, we can safely conclude that the observed NOE in the case of **1** indeed
44
45
46 belongs to the methyl group of *p*-cymene. Irradiation of the DOPC methylene resonance
47
48
49 at 1.37 ppm (Figure 2a) and of the diruthenium-complex aromatic proton resonances at
50
51
52 7.49 ppm (Figure 2c) did not give rise to intermolecular NOEs. Therefore, the only
53
54
55
56
57
58
59
60

intermolecular NOE observed is a hint that the diruthenium complex is likely to be located on the surface of the vesicle exterior or interior and not in between the layers. No NOE data are available for **3**, as this complex tends to precipitate over time during longer measurements.




Figure 2. Superimposed 1D NOE NMR spectra of **1** (1 mM) and DOPC (10 mM) vesicles in PBS/DMSO. Irradiated (a): 1.367 ppm; (b): 3.328 ppm; (c): 7.494 ppm. Mixing time 100

1
2
3 ms, relaxation delay 1s, 2048 scans, 8192 TD data points, acquisition time 511 ms,
4
5
6
7 spectral width 8012.8 Hz.
8
9

10
11 Upon addition of DHPC, no NOEs were observed between the diruthenium complexes
12
13 and the phospholipid chain and headgroup – only intramolecular NOEs were visible
14
15
16
17
18 (Figures S5 and S6).
19

20
21 *Diffusion spectroscopy:* When interacting with DOPC, the diffusion rate of the
22
23 diruthenium complexes should approach or even reach the diffusion rate of the vesicles
24
25 if we assume that all complexes interact with the vesicles. The DOSY spectra indeed
26
27 showed that when the diruthenium complexes **1** and **3** interact with DOPC vesicles, their
28
29 diffusion coefficient $D^{Ru\ complex}$ dropped to about the diffusion coefficient D^{DOPC} of the
30
31 vesicles (Figures 3 and S22). $D^{Ru\ complex}$ also decreased, but to a smaller extent, in the
32
33 case of **2**, which (a) is less soluble as compared to **1** and (b) exhibits a solubility that is
34
35 not significantly improved in the presence of DOPC compared to **3**. The fact that no
36
37 significant decrease of D^{DOPC} was observed in the presence of **1-3** is not surprising since
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4 DOPC vesicles are much larger than **1-3**, and their whole mass will only slightly change
5
6
7 upon interaction with the complexes **1-3**.
8
9

10 In the codissolution experiment, $D^{Ru\ complex}$ of **1** approached but did not reach D^{DOPC}
11
12 (Figure 4a). This means that a fraction of the complex interacted with the vesicle while
13
14 another fraction remained in solution. D^{DOPC} , on the other hand, seems to slightly
15
16 decrease in the presence of **1**. No changes were observed in the codissolution
17
18 experiment for **2** (Figure S23) as compared to the previous method (Fig. 3b). In the case
19
20 of **3**, codissolution with DOPC prior to vesicle formation led to a better solubility of
21
22 the complex. D^{DOPC} in the presence of **3** slightly decreased, as observed in the case of
23
24
25
26
27
28
29
30
31
32
33
34
35 **1**. The diffusion coefficient of **3** decreased practically to the one of DOPC vesicles (Figure
36
37
38 4b). It is conceivable that the slight decrease of D^{DOPC} in the presence of **1** and **3**, occurs
39
40
41 due to the presence of a higher amount of diruthenium complexes **1** and **3** associated
42
43 with the vesicles, which is enabled by codissolution. No changes (nor in the chemical shift
44
45 neither in the line broadening) were observed in the 1D 1H NMR spectra of **1-3** upon
46
47
48
49
50
51
52 codissolution with DOPC (Figure S24).
53
54
55
56
57
58
59
60





Figure 3. Overlay of DOSY spectra of (a): **1** (1 mM; blue), DOPC (10 mM; red) or mixture of both (green), respectively, dissolved in PBS (50 mM) / DMSO 4:1; (b): **2** (1 mM; blue), DOPC (10 mM; red) or mixture of both (green), respectively, dissolved in PBS (50 mM) / DMSO 4:1.



1
2
3 **Figure 4.** Overlay of DOSY spectra of (a): **1** (1 mM; blue), DOPC (10 mM; red) and **1**
4
5
6
7 codissolved with DOPC upon vesicle formation in PBS (50 mM) / DMSO 4:1 (green); (b):
8
9
10 **3** (1 mM; blue), DOPC (10 mM; red) and **3** codissolved with DOPC upon vesicle formation
11
12
13
14 in PBS (50 mM) / DMSO 4:1 (green).
15
16
17

18 The diffusion coefficient $D^{Ru\ complex}$ of **1** and **2** decreased significantly (Figure 5) upon
19
20
21 the addition of DHPC, while D^{DHPC} remained almost unchanged. In contrast to **1** and **2**,
22
23
24
25 $D^{Ru\ complex}$ of **3** remained unchanged (Figure S25). As already mentioned at the beginning
26
27
28 of this section, it needs to be considered that DHPC is present in two forms (micellar and
29
30
31 free) in solution. Diffusion coefficients observed for DHPC are a weighted average of free
32
33
34 and micellar species, free species being the major contributor. Here we should mention
35
36
37 that due to limited solubility of **1-3** it was not possible to use DHPC at a concentration
38
39
40 where most of the phospholipid would be present as micelles. At this concentration, the
41
42
43 NMR resonances of the diruthenium complexes **1-3** would be barely visible. As the
44
45
46 sparingly soluble complexes **1** and **2** interact with or become a part of micelles, their
47
48
49 diffusion coefficients become smaller than the average diffusion coefficient of DHPC.
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4 Accordingly, these $D^{Ru\ complex}$ values obtained for the diruthenium-complexes represent **1**
5
6
7 and **2** associated with micelles. The D^{DHPC} values, on the other hand, still represent
8
9
10 a weighted average, which hardly changes in the presence of the diruthenium-complexes,
11
12
13 since DHPC (28 mM) in the mixtures is present in large excess as compared to **1-3** (1
14
15
16 mM).
17
18
19

20
21 Analogous experiments were performed using DHPC well below CMC (10 mM). A
22
23
24 decrease in $D^{Ru\ complex}$ was also observed clearly for **1** and **2**, but no significant changes
25
26
27 were observed for **3** (Figure S26). The extent of the changes in $D^{Ru\ complex}$ for **1** and **2**
28
29
30 was, however, smaller than that observed when using DHPC above CMC. This indicates
31
32
33 that the diruthenium complexes either also interact with DHPC monomers forming larger
34
35
36 hetero-associates or that they lower the CMC of DHPC and promote the formation of
37
38
39 micelles⁵⁷ even at lower DHPC concentration. In any case, the DOSY data demonstrate
40
41
42 that **1** and **2** exhibit a pronounced affinity for interacting with the phospholipids, thereby
43
44
45
46
47
48
49 enhancing their solubility.
50
51
52
53
54
55
56
57
58
59
60




Figure 5. Overlay of DOSY spectra of (a): **1** (1 mM; blue), DHPC (28 mM; red) or mixture of both (green), respectively, dissolved in PBS (50 mM) / DMSO 4:1; (b): **2** (1 mM; blue), DHPC (28 mM; red) or mixture of both (green), respectively, dissolved in PBS (50 mM) / DMSO 4:1.

T_1 and T_2 relaxation: (i) Diruthenium complexes: When measuring the spin-lattice relaxation time (T_1), a significant decrease in T_1 was observed for several protons of complexes **1-3** when mixed with DOPC vesicles as can be seen in Figure S27. In the codissolution experiments, a similar tendency was observed but to a slightly smaller extent. Only relatively small changes (mainly slight decrease) in T_1 relaxation times were observed in complexes **1-3** in the presence of DHPC micelles (Figure S27).

1
2
3
4 (ii) DOPC: In the case of DOPC, a small decrease in T_1 was observed for the protons
5
6
7 of the phospholipid choline residue as well as of the aliphatic chain in the presence of **1-**
8
9
10 **3** (Figure S28). Very similar results were observed for DOPC from the codissolution
11
12
13
14 experiment with **1-3** (Figure S29).
15

16
17 (iii) DHPC: DHPC protons also showed a decrease in T_1 in the presence of **1-2** and to
18
19
20 a smaller extent also when mixed with **3**. Interestingly and in contrast to DOPC vesicles,
21
22
23
24 the protons of the aliphatic chain of DHPC were more affected (Figure S28) as compared
25
26
27
28 to the choline head.
29

30
31 While we observed a decrease of the T_1 relaxation times, the relation between T_1 and τ_c
32
33
34 is not straightforward, since the variation of T_1 as a function of τ_c is parabolic, and the
35
36
37
38 experimental determination of the minimum is demanding.⁵⁸
39

40
41
42 The measurement of the T_2 relaxation times is, therefore, an important complement since
43
44
45
46 T_2 decreases with increasing τ_c monotonously.
47

48
49 As compared to T_1 , the observed decrease in T_2 relaxation times of all selected protons
50
51
52 of complexes **1-3** in the presence of DHPC micelles was more consistent. When **1-3** were
53
54
55
56
57
58
59
60

1
2
3 present in suspension with DOPC vesicles, T_2 decreased significantly by about a factor
4
5
6
7 ten for most of the protons (Figure 6).
8
9

10 Similar to T_1 , the T_2 values of DHPC slightly dropped in the presence of the diruthenium
11
12
13 complexes **1-3** (Figure 7). The decrease was slightly more pronounced with complex **2**.
14
15
16 For DOPC vesicles present in suspension with **1-3**, the T_2 values of the choline dropped
17
18
19
20
21 clearly while those of the lipid chain were only slightly affected (Figure 7). We have noticed
22
23
24 similar results for the codissolution samples (Figure S30).
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60




Figure 6. T_2 relaxation time of (a): **1** (1 mM) protons; (b): **2** (1 mM) protons; (c): **3** (1 mM) protons in the presence of DOPC (10 mM) vesicles or DHPC (28 mM) micelles, respectively, in PBS (50 mM)/DMSO. Only results for resonances with no overlap with phospholipid signals shown. Due to insufficient S/N it was not possible to determine T_2 of *p*-cymene methyl protons in case of **3** in mixture with DHPC.




Figure 7. T_2 relaxation time of (a): DOPC (10 mM) vesicles or (b): DHPC (28 mM) micelles, respectively, in the presence of **1**, **2** and **3**, in PBS (50 mM)/DMSO. Only results for resonances with no overlap with signals of the complexes shown.

Putting the relaxation data together strongly suggest an interaction of the diruthenium complexes **1-3** with the DOPC vesicles. Furthermore, it is likely that the diruthenium complexes **1-3** are located on the surface of the phospholipid bilayer since the T_2


1
2
3 relaxation time of the choline residue in DOPC vesicles is the most affected in the
4
5
6
7 presence of **1-3**.
8
9

10 Likewise, the drop of the T_2 values of DHPC in the presence of the diruthenium
11
12 complexes **1-3** also points to an interaction between DHPC and **1-3**. In this case, the
13
14 decrease in T_2 was observed for β -CH₂, γ/δ -CH₂ and to a smaller extent also for the N-
15
16 methyl protons. The extent of the reduction in T_2 was thus selective and therefore not
17
18 solely caused by a decrease in the overall tumbling of the micelles. Local restriction in
19
20 mobility of the corresponding chain segments through interaction with the complex is most
21
22 likely responsible for the observed drop in T_2 . However, changes in the local orientation
23
24 or order of the segments and consequently their solvent exposure may also contribute
25
26
27 here.
28
29
30
31
32
33
34
35
36
37
38
39
40

41 The codissolution of the diruthenium complexes with DOPC prior to vesicle formation
42
43 did not significantly change the relaxation times of the protons considered when
44
45 compared to the procedure of adding the complexes to preformed vesicles in solution.
46
47
48
49
50

51 ***Lanthanide shift experiments:*** The paramagnetic lanthanide ion Pr³⁺ in solution is long known
52
53 and used for inducing chemical shift changes and line broadening of NMR resonances of nuclei in
54
55
56
57
58
59
60

1
2
3 close proximity, thus enabling the identification of coordination atoms or binding pockets for
4 proteins and enzymes.⁵⁹ Since Pr^{3+} does not penetrate phospholipid bilayers,⁶⁰ it will induce
5 chemical shift change and line broadening only for the nuclei of the outer phospholipid layer,
6 allowing to distinguish interior and exterior of a vesicle as can be seen in ^{31}P NMR spectra of
7 DOPC vesicles (Figure 8). The resonance of the phosphocholine head groups exposed to the
8 exterior solution where PrCl_3 is present is shifted by about 12.3 ppm downfield as compared to
9 the unperturbed resonance. Therefore, the phosphocholine signals that show no shift can be
10 attributed to the interior layer of the vesicles where no Pr^{3+} is present. When both **1** and PrCl_3 are
11 present in solution, the difference in the ^{31}P shift is only about 5.6 ppm indicating that some of the
12 surface is already occupied by (also positively charged) **1**. With this experiment, we cannot
13 however, exclude that **1** is also present inside the DOPC vesicle.



1
2
3 **Figure 8.** ^{31}P NMR of (a): DOPC (10 mM) vesicles and **1** (1 mM) in presence of 1 mM
4
5
6
7 PrCl_3 in $\text{D}_2\text{O}/\text{DMSO}$, (b): DOPC (10 mM) and **1** (1 mM) in $\text{D}_2\text{O}/\text{DMSO}$, (c): DOPC (10 mM)
8
9
10 vesicles and PrCl_3 (1 mM) in $\text{D}_2\text{O}/\text{DMSO}$, (d): DOPC (10 mM) vesicles in $\text{D}_2\text{O}/\text{DMSO}$.

11
12
13
14 ^1H NMR spectra showed similar results (Figure 9) - the resonances of the N-methyl protons were
15
16 split and shifted in the presence of Pr^{3+} (Figure 9b). Additionally, a shoulder was observed for the
17
18 N-methyl protons of the inner layer at 3.33 ppm in the presence of Pr^{3+} (Figure 9b), which might
19
20 be caused by the polydispersity of the vesicles.
21
22

23
24 Interestingly, when both Pr^{3+} and **1** were present, the shoulder of the N-methyl protons of the
25
26 inner layer disappeared, and a new splitting of the N-methyl protons belonging to the exterior layer
27
28 was observed (Figure 9d). This could be due to some of the exterior choline heads being
29
30 exposed to Pr^{3+} while others being influenced by both **1** and Pr^{3+} together.
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60




Figure 9. ^1H NMR of (a): DOPC (10 mM) vesicles in $\text{D}_2\text{O}/\text{DMSO}$, (b): DOPC (10 mM) vesicles in presence of 1 mM PrCl_3 in $\text{D}_2\text{O}/\text{DMSO}$, (c): DOPC (10 mM) vesicles and **1** (1 mM) in $\text{D}_2\text{O}/\text{DMSO}$, (d): DOPC (10 mM) vesicles, **1** (1 mM) and PrCl_3 (1 mM) in $\text{D}_2\text{O}/\text{DMSO}$.

Membrane passage: DOPC and a number of other phospholipids commonly used for model studies are zwitterionic. Nevertheless, the surface of zwitterionic phospholipid vesicles tends to be negatively charged, presumably due to the cationic N-methyl choline moiety being surrounded by anions in suspension.^{61,62} Negative surface charge can

1
2
3 attract cationic diruthenium complexes towards DOPC vesicles. This is in line with what
4
5
6
7 we have observed in our NMR study – the diruthenium complexes seem to be located
8
9
10 close to the surface.

11
12
13
14 **1-3** are intermediate/large sized cations possessing a nearly spherical shape,
15
16
17 their charge is balanced by Cl⁻ or BF₄⁻ counterions, respectively. Hydrophobic cations are
18
19
20 known to be able to permeate lipid bilayers⁶³ which has been observed not only for
21
22
23 organic cations, but also for metal complexes.⁶⁴ The negative electric potential inside
24
25
26 mitochondria is assumed to be a driving force for hydrophobic cations to enter the
27
28
29 organelle.^{14,65} This effect may be standing behind the diruthenium complex route to
30
31
32 mitochondria.
33
34
35
36
37

38 CONCLUSIONS Lipophilicity of compounds is long known to influence the interactions
39
40
41 with membranes and their passage, and thus it often controls the toxicity and efficacy of
42
43
44 drugs. As previously established, symmetrical diruthenium complexes $[(\eta^6\text{-}p\text{-}$
45
46 $\text{MeC}_6\text{H}_4\text{Pr}^i)_2\text{Ru}_2(\text{R})_3]^+$ for which the calculated log *P* values of the individual thiol ligands
47
48
49 range between 3.5-4.0 were those exhibiting the lowest IC₅₀ values against cancer
50
51
52
53
54
55
56 cells.^{1,5}
57
58
59
60

1
2
3
4 We have evaluated the interactions of three diruthenium complexes with phospholipid
5
6
7 membrane models using NMR spectroscopy. Based on 1D NMR spectra, ^1H and ^{31}P
8
9
10 chemical shift changes, DOSY and relaxation data, we can conclude that the diruthenium
11
12
13 complexes **1-3** interact with DOPC vesicles, especially the most water-soluble and
14
15
16 lipophilic diruthenium complex **1**. Overall, the very high *in vitro* activity of **1** can be
17
18
19 correlated to its ability to interact with the membrane as well as to its solubility.
20
21
22 Importantly, the data also demonstrate that diruthenium complexes interact with
23
24
25 phospholipids while maintaining their structural integrity. Both factors are important
26
27
28 prerequisites for intracellular redistribution of the complexes among cell organelles such
29
30
31 as mitochondria.
32
33
34
35
36
37

38 NOE and relaxation data indicated that the complexes are interacting with the choline
39
40
41 headgroups and are located at the vesicle surface reaching into the membrane
42
43
44 surface/water interface. The results obtained with **1** when Pr^{3+} was added suggest that
45
46
47 the complex is located on the exterior of the vesicles. Taken all results together, we can
48
49
50 conclude that the complexes most likely do not reside between the two phospholipid
51
52
53
54
55
56
57
58
59
60

1
2
3 layers and that - at least initially - membrane association in the head group region is most
4
5
6
7 likely involving electrostatic interactions.
8
9

10 To some extent, the complexes also interacted with dynamic phospholipid species, as
11
12 observed in the case of DHPC micelle/free phospholipid solutions. Additionally,
13
14 the presence of the complexes in DHPC solutions below CMC induced the formation of
15
16 micelles or aggregates. These studies indicated that the diruthenium complexes also
17
18 exhibit a certain affinity for the phospholipid chain. However, dynamics of DOPC bilayer
19
20 (together with hydrophobic effect) may be preventing fast passive transmembrane
21
22 passage so that interactions with the membrane surface prevail.
23
24
25
26
27
28
29
30
31
32
33

34 There are certain limitations in our study that need to be considered. While DMSO is a
35
36 common co-solvent for drug in vitro studies, it can cause membrane perturbations and is
37
38 known to form clusters with water and in this way could have an influence in our study as
39
40 well. Further, while the phospholipid-complex mixtures remain stable in terms of NMR-
41
42 experiments, leakage from the vesicles cannot be excluded.
43
44
45
46
47
48
49
50
51

52 In summary, the data suggest that diruthenium complexes are probably not only
53
54 entering cells by passive diffusion, and that additional uptake mechanisms are likely
55
56
57
58
59
60

1
2
3 involved. Recently, affinity chromatography using extracts from *T. gondii*-infected human
4
5
6
7 fibroblasts led to the identification of TgEF1 as well as its human homologue as major
8
9
10 targets of the similar, highly *in vitro* active complex $[(\eta^6\text{-}p\text{-MeC}_6\text{H}_4\text{Pr}^t)_2\text{Ru}_2(\text{R}^1)_2(\text{R}^2)]^+$ (R^1
11
12
13 = $\text{SC}_6\text{H}_4\text{-}p\text{-Bu}^t$, $\text{R}^2 = \text{SC}_6\text{H}_4\text{-}p\text{-OH}$) and various other host proteins were found to bind to
14
15
16
17 this as well.¹⁰
18
19
20

21 In the context of recent findings using ICP-MS showing a significant amount of
22
23 ruthenium present within mitochondria of treated cells and parasites,^{5,10} and that the
24
25 apoptotic event in cancer cells treated with $[(\eta^6\text{-}p\text{-MeC}_6\text{H}_4\text{Pr}^t)_2\text{Ru}_2(\text{R})_3]^+$ ($\text{R} = \text{SC}_6\text{H}_4\text{-}p\text{-}$
26
27
28 Bu^t) was confirmed by the decrease in the mitochondrial membrane potential ($\Delta\psi_m$),⁶⁶ the
29
30
31 following mechanism appears plausible: the cationic lipophilic complex enters the cell or
32
33
34 the parasite and targets mitochondria attracted by their negative potential. Subsequently,
35
36
37
38 it passes through the outer mitochondrial membrane, and (a) remains adsorbed to
39
40
41
42 the outer surface of the inner membrane or (b) remains in the intermembrane space and
43
44
45
46
47
48
49 perturbs the electron transport chain. It appears less probable that the diruthenium
50
51
52
53 complexes enter the mitochondrial matrix, since the inner membrane does not contain
54
55
56
57
58
59
60

1
2
3 porins, and all molecules require special membrane transporters to enter or exit the
4
5
6
7 matrix.

8
9
10 In order to get more insights into the exact targets and mechanisms of action(s) of
11
12
13 diruthenium complexes, further studies will be required, possibly involving membrane
14
15
16
17 potential or specific uptake inhibitors and stripping off the outer mitochondrial
18
19
20 membrane. The knowledge will aid further development and optimization of efficient
21
22
23 diruthenium complexes as potential anti-cancer and antiparasitic drugs.
24
25
26
27

28 ASSOCIATED CONTENT

29
30
31
32
33 **Supporting Information.** Figures S1-2: DOSY-based CMC estimation. Figure S3: ^1H
34
35 NMR of DHPC with concentrations varied. Figures S4-6: NOE spectra. Figures S7-8:
36
37 DOSY fitting plots for DOPC and DHPC. Figure S9: DLS. Table S1-3: Chemical shift
38
39 changes in the presence of phospholipids. Figure S10: ^1H NMR DOPC assignment.
40
41
42
43
44 Figure S11: ^1H NMR DHPC assignment. Figures S12-14: ^1H NMR of **1-3** in the
45
46
47 presence of DOPC. Figures S15-17 ESI-MS. Figures S18-20: ^1H NMR of **1-3** in the
48
49
50 presence of DHPC. Figure S21: ^{31}P NMR spectra. Figure S22: DOSY of **3** in the
51
52
53
54
55
56
57
58
59
60

1
2
3 presence of DOPC. Figure S23: **2** codissolution with DOPC. Figure S24: ^1H NMR of
4
5
6
7 DOPC codissolved with **1-3**. Figure S25: DOSY of **3** in the presence of DHPC. Figure
8
9
10 S26: DOSY of sub-CMC DHPC in the presence of **1-3**. Figure S27: T_1 relaxation of **1-3**
11
12
13 in presence of DOPC and DHPC. Figure S28: T_1 relaxation of DOPC and DHPC in
14
15
16
17 presence of **1-3**. Figure S29: T_1 relaxation of DOPC codissolved with **1-3**. Figure S30:
18
19
20
21 T_2 relaxation of DOPC codissolved with **1-3**.
22
23

24 The following files are available free of charge.

25
26
27 Supporting information (PDF)
28
29
30

31 AUTHOR INFORMATION

32 33 34 35 36 Corresponding Authors

37
38
39
40 *julien.furrer@dcb.unibe.ch; Tel.: +41 31 631 4383
41
42

43
44
45 [*martina.vermathen@dcb.unibe.ch](mailto:martina.vermathen@dcb.unibe.ch); Tel.: +41 31 631 3948
46
47

48
49 [*hedvika.primasova@dcb.unibe.ch](mailto:hedvika.primasova@dcb.unibe.ch); Tel.: +41 31 631 4384
50
51

52 53 Author Contributions

1
2
3
4 The manuscript was written through contributions of all authors. All authors have given
5
6
7 approval to the final version of the manuscript.
8
9

10 11 ACKNOWLEDGMENT 12

13
14
15
16 We are very grateful to Lisa Rahnfeld and Paola Luciani of the Department of Chemistry
17
18
19 and Biochemistry, University of Bern for the viscosity measurement, for introducing us
20
21
22 to their DLS device and letting us use it. The authors acknowledge financial support
23
24
25
26 from the University of Bern.
27
28
29

30 31 ABBREVIATIONS 32

33 CMC critical micelle concentration, COSY correlation spectroscopy, CPMG Carr-
34
35
36 Purcell-Meiboom-Gill, DHPC 1,2-dihexanoyl-*sn*-glycero-3-phosphocholine, DLS dynamic
37
38
39 light scattering, DMSO dimethyl sulfoxide, DOPC 1,2-dioleoyl-*sn*-glycero-3-
40
41
42 phosphocholine, DOSY diffusion ordered spectroscopy, HMBC heteronuclear multiple
43
44
45 bond correlation (spectroscopy), HSQC heteronuclear single quantum coherence
46
47
48 (spectroscopy), ICP-MS inductively coupled plasma mass spectrometry, MS mass
49
50
51 spectrometry, NMR nuclear magnetic resonance (spectroscopy), NOE nuclear
52
53
54
55
56
57
58
59
60

1
2
3 Overhauser effect, PBS phosphate-buffered saline, PDI polydispersity index, ROS
4
5
6
7 reactive oxygen species, TEM transmission electron microscopy.
8
9

10 REFERENCES
11

- 12
13
14 (1) Furrer, J.; Süss-Fink, G. Thiolato-Bridged Dinuclear Arene Ruthenium Complexes
15
16
17 and Their Potential as Anticancer Drugs. *Coord. Chem. Rev.* **2016**, *309*, 36–50.
18
19
20
21 <https://doi.org/10.1016/j.ccr.2015.10.007>.
22
23
24
25 (2) Giannini, F.; Geiser, L.; Paul, L. E. H.; Roder, T.; Therrien, B.; Süss-Fink, G.; Furrer,
26
27
28
29 J. Tuning the in Vitro Cell Cytotoxicity of Dinuclear Arene Ruthenium Trithiolato
30
31
32
33
34
35
36
37
38
39
40
41 (3) Giannini, F.; Paul, L. E. H.; Furrer, J.; Therrien, B.; Süss-Fink, G. Highly Cytotoxic
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56 (4) Primasová; Paul; Diserens; Primasová; Vermathen; Vermathen; Furrer. ¹H HR-
57
58
59
60

- 1
2
3
4 MAS NMR-Based Metabolomics of Cancer Cells in Response to Treatment with
5
6
7 the Diruthenium Trithiolato Complex [(p-MeC₆H₄iPr)₂Ru₂(SC₆H₄-p-But)₃]⁺
8
9
10 (DiRu-1). *Metabolites* **2019**, *9*(7), 146. <https://doi.org/10.3390/metabo9070146>.
11
12
13
14
15 (5) Basto, A. P.; Anghel, N.; Rubbiani, R.; Müller, J.; Stibal, D.; Giannini, F.; Süss-Fink,
16
17
18 G.; Balmer, V.; Gasser, G.; Furrer, J.; et al. Targeting of the Mitochondrion by
19
20
21
22 Dinuclear Thiolato-Bridged Arene Ruthenium Complexes in Cancer Cells and in the
23
24
25 Apicomplexan Parasite *Neospora Caninum*. *Metallomics* **2019**, *11*, 462–474.
26
27
28
29 <https://doi.org/10.1039/c8mt00307f>.
30
31
32
33 (6) Tomšík, P.; Muthná, D.; Řezáčová, M.; Mičuda, S.; Čmielová, J.; Hroch, M.;
34
35
36 Endlicher, R.; Červinková, Z.; Rudolf, E.; Hann, S.; et al. [(P-
37
38
39 MeC₆H₄Pri)₂Ru₂(SC₆H₄-p-But)₃]Cl (Diruthenium-1), a Dinuclear Arene
40
41
42
43 Ruthenium Compound with Very High Anticancer Activity: An in Vitro and in Vivo
44
45
46
47 Study. *J. Organomet. Chem.* **2015**, *782*, 42–51.
48
49
50
51 <https://doi.org/10.1016/j.jorganchem.2014.10.050>.
52
53
54
55 (7) Koceva-Chyła, A.; Matczak, K.; Hikisz, M. P.; Durka, M. K.; Kochel, M. K.; Süss-

- 1
2
3
4 Fink, G.; Furrer, J.; Kowalski, K. Insights into the in Vitro Anticancer Effects of
5
6
7 Diruthenium-1. *ChemMedChem* **2016**, *2*, 2171–2187.
8
9
10 <https://doi.org/10.1002/cmdc.201600315>.
11
12
13
14
15 (8) Muthná, D.; Tomšík, P.; Havelek, R.; Köhlerová, R.; Kasilingam, V.; Čermáková,
16
17
18 E.; Stíbal, D.; Řezáčová, M.; Süß-Fink, G. In-Vitro and in-Vivo Evaluation of the
19
20
21
22 Anticancer Activity of Diruthenium-2, a New Trithiolato Arene Ruthenium Complex
23
24
25 [(H6-p-MeC6H4Pri)2Ru2(μ-S-p-C6H4OH)3]Cl. *Anticancer. Drugs* **2016**, *27* (7),
26
27
28 643–650. <https://doi.org/10.1097/CAD.0000000000000374>.
29
30
31
32
33 (9) Giannini, F.; Süß-Fink, G.; Furrer, J. Efficient Oxidation of Cysteine and
34
35
36
37 Glutathione Catalyzed by a Dinuclear Areneruthenium Trithiolato Anticancer
38
39
40
41 Complex. *Inorg. Chem.* **2011**, *50* (21), 10552–10554.
42
43
44 <https://doi.org/10.1021/ic201941j>.
45
46
47
48 (10) Basto, A. P.; Müller, J.; Rubbiani, R.; Stíbal, D.; Giannini, F.; Süß-Fink, G.; Balmer,
49
50
51
52 V.; Hemphill, A.; Gasser, G.; Furrer, J. Characterization of the Activities of Dinuclear
53
54
55
56 Thiolato-Bridged Arene Ruthenium Complexes against *Toxoplasma Gondii*.
57
58
59
60

- 1
2
3
4 *Antimicrob. Agents Chemother.* **2017**, *61* (9), e01031-17.
5
6
7
- 8 (11) Shinoda, W. Permeability across Lipid Membranes. *Biochim. Biophys. Acta -*
9
10
11 *Biomembr.* **2016**, *1858* (10), 2254–2265.
12
13
14
15 <https://doi.org/10.1016/j.bbamem.2016.03.032>.
16
17
18
- 19 (12) Missner, A.; Pohl, P. 110 Years of the Meyer-Overton Rule: Predicting Membrane
20
21
22
23 Permeability of Gases and Other Small Compounds. *ChemPhysChem* **2009**, *10*,
24
25
26 1405–1414.
27
28
29
- 30 (13) Bourgaux, C.; Couvreur, P. Interactions of Anticancer Drugs with Biomembranes:
31
32
33
34 What Can We Learn from Model Membranes? *J. Control. Release* **2014**, *190*, 127–
35
36
37 138. <https://doi.org/10.1016/j.jconrel.2014.05.012>.
38
39
40
41
- 42 (14) Liberman, E. A.; Topaly, V. P.; Tsofina, L. M.; Jasaitis, A. A.; Skulachev, V. P.
43
44
45
46 Mechanism of Coupling of Oxidative Phosphorylation and the Membrane Potential
47
48
49 of Mitochondria. *Nature* **1969**, *222*, 1076–1078.
50
51
52
53
- 54 (15) Murphy, M. P. Targeting Lipophilic Cations to Mitochondria. *Biochim. Biophys. Acta*
55
56
57
58
59
60

1
2
3 - *Bioenerg.* **2008**, *1777* (7–8), 1028–1031.

4
5
6
7 <https://doi.org/10.1016/j.bbabbio.2008.03.029>.

8
9
10
11 (16) Gasser, G.; Metzler-Nolte, N. The Potential of Organometallic Complexes in

12
13
14 Medicinal Chemistry. *Curr. Opin. Chem. Biol.* **2012**, *16* (1–2), 84–91.

15
16
17
18 <https://doi.org/10.1016/j.cbpa.2012.01.013>.

19
20
21
22 (17) Giannini, F.; Furrer, J.; Ibao, A. F.; Süß-Fink, G.; Therrien, B.; Zava, O.; Baquie,

23
24
25
26 M.; Dyson, P. J.; Štěpnička, P. Highly Cytotoxic Trithiophenolatodiruthenium

27
28
29
30 Complexes of the Type [(H6-p-MeC6H4Pr i) 2Ru2(SC6H4-p-X)3] +: Synthesis,

31
32
33
34 Molecular Structure, Electrochemistry, Cytotoxicity, and Glutathione Oxidation

35
36
37 Potential. *J. Biol. Inorg. Chem.* **2012**, *17* (6), 951–960.

38
39
40
41 <https://doi.org/10.1007/s00775-012-0911-2>.

42
43
44 (18) Deleu, M.; Crowet, J. M.; Nasir, M. N.; Lins, L. Complementary Biophysical Tools

45
46
47
48 to Investigate Lipid Specificity in the Interaction between Bioactive Molecules and

49
50
51
52 the Plasma Membrane: A Review. *Biochim. Biophys. Acta - Biomembr.* **2014**, *1838*

53
54
55
56 (12), 3171–3190. <https://doi.org/10.1016/j.bbamem.2014.08.023>.

- 1
2
3
4 (19) Alves, A. C.; Ribeiro, D.; Nunes, C.; Reis, S. Biophysics in Cancer: The Relevance
5
6
7 of Drug-Membrane Interaction Studies. *Biochim. Biophys. Acta - Biomembr.* **2016**,
8
9
10 *1858* (9), 2231–2244. <https://doi.org/10.1016/j.bbamem.2016.06.025>.
11
12
13
14
15 (20) Peetla, C.; Stine, A.; Labhasetwar, V. Biophysical Interactions with Model Lipid
16
17
18 Membranes: Applications in Drug Discovery and Drug Delivery. *Mol. Pharm.* **2009**,
19
20
21 *6* (5), 1264–1276. <https://doi.org/10.1021/mp9000662>.
22
23
24
25
26 (21) Clark, T. D.; Bartolotti, L.; Hicks, R. P. The Application of DOSY NMR and Molecular
27
28
29 Dynamics Simulations to Explore the Mechanism(s) of Micelle Binding of
30
31
32 Antimicrobial Peptides Containing Unnatural Amino Acids. *Biopolymers* **2013**, *99*
33
34
35
36
37 (8), 548–561. <https://doi.org/10.1002/bip.22215>.
38
39
40
41 (22) McBain, J. W.; Salmon, C. S. Colloidal Electrolytes. Soap Solutions and Their
42
43
44 Constitution. *J. Am. Chem. Soc.* **1920**, *42* (3), 426–460.
45
46
47
48 <https://doi.org/10.1021/ja01448a010>.
49
50
51
52 (23) Brand, T.; Cabrita, E. J.; Berger, S. Intermolecular Interaction as Investigated by
53
54
55
56
57
58
59
60

- 1
2
3
4 NOE and Diffusion Studies. *Prog. Nucl. Magn. Reson. Spectrosc.* **2005**, *46* (4),
5
6
7 159–196. <https://doi.org/10.1016/j.pnmrs.2005.04.003>.
8
9
10
11 (24) Vermathen, M.; Vermathen, P.; Simonis, U.; Bigler, P. Time-Dependent
12
13
14 Interactions of the Two Porphyrinic Compounds Chlorin E6 and Mono-L-Aspartyl-
15
16
17 Chlorin E6 with Phospholipid Vesicles Probed by NMR Spectroscopy. *Langmuir*
18
19
20
21
22 **2008**, *24* (21), 12521–12533. <https://doi.org/10.1021/la802040v>.
23
24
25
26 (25) Jensen, M.; Bjerring, M.; Nielsen, N. C.; Nerdal, W. Cisplatin Interaction with
27
28
29 Phosphatidylserine Bilayer Studied by Solid-State NMR Spectroscopy. *J. Biol.*
30
31
32
33
34 *Inorg. Chem.* **2010**, *15* (2), 213–223. <https://doi.org/10.1007/s00775-009-0586-5>.
35
36
37
38 (26) Crans, D. C.; Rithner, C. D.; Baruah, B.; Gourley, B. L.; Levinger, N. E. Molecular
39
40
41 Probe Location in Reverse Micelles Determined by NMR Dipolar Interactions. *J.*
42
43
44
45 *Am. Chem. Soc.* **2006**, *128* (13), 4437–4445. <https://doi.org/10.1021/ja0583721>.
46
47
48
49 (27) Scheidt, H. A.; Huster, D. The Interaction of Small Molecules with Phospholipid
50
51
52
53 Membranes Studied by ¹H NOESY NMR under Magic-Angle Spinning. *Acta*
54
55
56
57
58
59
60

1
2
3
4 *Pharmacol. Sin.* **2008**, *29* (1), 35–49. <https://doi.org/10.1111/j.1745->
5
6
7 7254.2008.00726.x.
8
9

10
11 (28) Vermathen, M.; Marzorati, M.; Vermathen, P.; Bigler, P. PH-Dependent Distribution
12
13 of Chlorin E6 Derivatives across Phospholipid Bilayers Probed by NMR
14
15 Spectroscopy. *Langmuir* **2010**, *26* (13), 11085–11094.
16
17
18
19 <https://doi.org/10.1021/la100679y>.
20
21
22
23

24
25
26 (29) Marzorati, M.; Bigler, P.; Vermathen, M. Interactions between Selected
27
28 Photosensitizers and Model Membranes: An NMR Classification. *Biochim. Biophys.*
29
30 *Acta - Biomembr.* **2011**, *1808* (6), 1661–1672.
31
32
33
34 <https://doi.org/10.1016/j.bbamem.2011.02.011>.
35
36
37
38

39
40
41 (30) Vermathen, M.; Marzorati, M.; Bigler, P. Self-Assembling Properties of Porphyrinic
42
43 Photosensitizers and Their Effect on Membrane Interactions Probed by NMR
44
45 Spectroscopy. *J. Phys. Chem. B* **2013**, *117* (23), 6990–7001.
46
47
48
49 <https://doi.org/10.1021/jp403331n>.
50
51
52
53

- 1
2
3
4 (31) Li, H.; Zhao, T.; Sun, Z. Analytical Techniques and Methods for Study of Drug-Lipid
5
6 Membrane Interactions. *Rev. Anal. Chem.* **2018**, *37* (1), 1–23.
7
8
9
10 <https://doi.org/10.1515/revac-2017-0012>.
11
12
13
14
15 (32) Söderman, O.; Stilbs, P. NMR Studies of Complex Surfactant Systems. *Prog. Nucl.*
16
17 *Magn. Reson. Spectrosc.* **1994**, *26* (PART 5), 445–482.
18
19
20
21 [https://doi.org/10.1016/0079-6565\(94\)80013-8](https://doi.org/10.1016/0079-6565(94)80013-8).
22
23
24
25
26 (33) Stíbal, D.; Therrien, B.; Süß-Fink, G.; Nowak-Sliwinska, P.; Dyson, P. J.;
27
28 Čermáková, E.; Řezáčová, M.; Tomšík, P. Chlorambucil Conjugates of Dinuclear
29
30 P-Cymene Ruthenium Trithiolato Complexes: Synthesis, Characterization and
31
32 Cytotoxicity Study in Vitro and in Vivo. *J. Biol. Inorg. Chem.* **2016**, *21* (4), 443–452.
33
34
35
36
37 <https://doi.org/10.1007/s00775-016-1353-z>.
38
39
40
41
42
43
44
45 (34) Stibal, D. Thiolato-Bridged Arene Ruthenium Complexes as Anticancer Agents,
46
47
48 Université de Neuchâtel, 2015.
49
50
51
52
53 (35) Söderman, O.; Stilbs, P.; Price, W. S. NMR Studies of Surfactants. *Concepts Magn.*
54
55
56
57
58
59
60

1
2
3
4 *Reson. Part A Bridg. Educ. Res.* **2004**, *23* (2), 121–135.

5
6
7 <https://doi.org/10.1002/cmr.a.20022>.

- 8
9
10
11 (36) Schick, M. J. Effect of Temperature on the Critical Micelle Concentration of
12
13
14
15 Nonionic Detergents. Thermodynamics of Micelle Formation 1 . *J. Phys. Chem.*
16
17
18 **2007**, *67*(9), 1796–1799. <https://doi.org/10.1021/j100803a013>.
19
20
21
22
23 (37) Dua, J. S.; Rana, A. C.; Bhandari, A. K. Liposomes - Methodology and Applications.
24
25
26 *Int. J. Pharm. Stud. Res.* **2012**, *3*, 14–20.
27
28
29
30
31 (38) Stott, K.; Keeler, J.; Van, Q. N.; Shaka, A. J. One-Dimensional NOE Experiments
32
33
34 Using Pulsed Field Gradients. *J. Magn. Reson.* **1997**, *125* (2), 302–324.
35
36
37 <https://doi.org/10.1006/jmre.1997.1110>.
38
39
40
41
42 (39) Wu, D. H.; Chen, A.; Johnson, C. S. An Improved Diffusion-Ordered Spectroscopy
43
44
45 Experiment Incorporating Bipolar-Gradient Pulses. *Journal of Magnetic*
46
47
48 *Resonance, Series A.* 1995, pp 260–264. <https://doi.org/10.1006/jmra.1995.1176>.
49
50
51
52
53 (40) Stejskal, E. O.; Tanner, J. E. Spin Diffusion Measurements: Spin Echoes in the
54
55
56
57
58
59
60

- 1
2
3
4 Presence of a Time-Dependent Field Gradient. *J. Chem. Phys.* **1965**, *42* (1), 288–
5
6
7 292. <https://doi.org/10.1063/1.1695690>.
8
9
10
11 (41) Carr, H. Y.; Purcell, E. M. Effects of Diffusion on Free Precession in Nuclear
12
13
14
15 Magnetic Resonance Experiments. *Phys. Rev.* **1954**, *94* (3), 630–638.
16
17
18
19 (42) Meiboom, S.; Gill, D. Modified Spin-Echo Method for Measuring Nuclear Relaxation
20
21
22
23 Times. *Rev. Sci. Instrum.* **1958**, *29* (8), 688–691.
24
25
26
27 <https://doi.org/10.1063/1.1716296>.
28
29
30
31 (43) Gabriel, N. E.; Roberts, M. F. Spontaneous Formation of Stable Unilamellar
32
33
34
35 Vesicles. *Biochemistry* **1984**, *23* (18), 4011–4015.
36
37
38
39 <https://doi.org/10.1021/bi00313a001>.
40
41
42 (44) Giannini, F.; Furrer, J.; Süss-Fink, G.; Clavel, C. M.; Dyson, P. J. Synthesis,
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

- 1
2
3
4 48. <https://doi.org/10.1016/j.jorganchem.2013.04.049>.
5
6
7
8 (45) Schreier, S.; Malheiros, S. V. P.; De Paula, E. Surface Active Drugs: Self-
9
10
11 Association and Interaction with Membranes and Surfactants. Physicochemical and
12
13
14 Biological Aspects. *Biochim. Biophys. Acta - Biomembr.* **2000**, *1508* (1–2), 210–
15
16
17
18 234. [https://doi.org/10.1016/S0304-4157\(00\)00012-5](https://doi.org/10.1016/S0304-4157(00)00012-5).
19
20
21
22
23 (46) Chou, J. J.; Baber, J. L.; Bax, A. Characterization of Phospholipid Mixed Micelles
24
25
26 by Translational Diffusion. *J. Biomol. NMR* **2004**, *29* (3), 299–308.
27
28
29
30 <https://doi.org/10.1023/B:JNMR.0000032560.43738.6a>.
31
32
33
34 (47) Björnerås, J.; Nilsson, M.; Mäler, L. Analysing DHPC/DMPC Bicelles by Diffusion
35
36
37
38 NMR and Multivariate Decomposition. *Biochim. Biophys. Acta - Biomembr.* **2015**,
39
40
41 *1848* (11), 2910–2917. <https://doi.org/10.1016/j.bbamem.2015.09.002>.
42
43
44
45
46 (48) Lin, T. L.; Chen, S. H.; Gabriel, N. E.; Roberts, M. F. Use of Small-Angle Neutron
47
48
49 Scattering To Determine the Structure and Interaction of
50
51
52
53 Dihexanoylphosphatidylcholine Micelles. *J. Am. Chem. Soc.* **1986**, *108* (12), 3499–
54
55
56
57
58
59
60

1
2
3
4 3507. <https://doi.org/10.1021/ja00272a055>.
5
6
7

8 (49) Lipfert, J.; Columbus, L.; Chu, X. V. B.; Lesley, S. A. Size and Shape of Detergent
9
10
11 Micelles Determined by Small-Angle X-Ray Scattering. *J. Phys. Chem. B* **2007**,
12
13
14
15 12427–12438.
16
17

18
19 (50) Pianet, I.; André, Y.; Ducasse, M. A.; Tarascou, I.; Lartigue, J. C.; Pinaud, N.;
20
21
22
23 Fouquet, E.; Dufourc, E. J.; Laguerre, M. Modeling Procyanidin Self-Association
24
25
26 Processes and Understanding Their Micellar Organization: A Study by Diffusion
27
28
29
30 NMR and Molecular Mechanics. *Langmuir* **2008**, *24* (19), 11027–11035.
31
32
33
34 <https://doi.org/10.1021/la8015904>.
35
36
37

38 (51) Hughes, Z. E.; Mark, A. E.; Mancera, R. L. Molecular Dynamics Simulations of the
39
40
41 Interactions of DMSO with DPPC and DOPC Phospholipid Membranes. *J. Phys.*
42
43
44
45 *Chem. B* **2012**, *116* (39), 11911–11923. <https://doi.org/10.1021/jp3035538>.
46
47
48

49 (52) Šteflová, J.; Štefl, M.; Walz, S.; Knop, M.; Trapp, O. Comprehensive Study on
50
51
52
53 Critical Micellar Concentrations of SDS in Acetonitrile-Water Solvents.
54
55
56
57
58
59
60

1
2
3
4 *Electrophoresis* 2016, 37 (10), 1287–1295.

5
6
7 <https://doi.org/10.1002/elps.201500553>.

- 8
9
10
11 (53) Zhou, Z.; Sayer, B. G.; Hughes, D. W.; Stark, R. E.; Eppard, R. M. Studies of
12
13
14
15 Phospholipid Hydration by High-Resolution Magic-Angle Spinning Nuclear
16
17
18 Magnetic Resonance. *Biophys. J.* 1999, 76 (1), 387–399.

19
20
21
22 [https://doi.org/10.1016/S0006-3495\(99\)77205-X](https://doi.org/10.1016/S0006-3495(99)77205-X).

- 23
24
25
26 (54) Fernández, C.; Hilty, C.; Wider, G.; Wüthrich, K. Lipid-Protein Interactions in DHPC
27
28
29
30 Micelles Containing the Integral Membrane Protein OmpX Investigated by NMR
31
32
33 Spectroscopy. *Proc. Natl. Acad. Sci. U. S. A.* 2002, 99 (21), 13533–13537.

34
35
36
37 <https://doi.org/10.1073/pnas.212515099>.

- 38
39
40
41 (55) Jeener, J.; Meier, B. H.; Bachmann, P.; Ernst, R. R. Investigation of Exchange
42
43
44
45 Processes by Two-Dimensional NMR Spectroscopy. *J. Chem. Phys.* 1979, 71(11),
46
47
48 4546–4553. <https://doi.org/10.1063/1.438208>.

- 49
50
51
52 (56) Noggle, J. H.; Schirmer, R. E. *The Nuclear Overhauser Effect: Chemical*
53
54
55
56
57
58
59
60

1
2
3
4 *Applications*; Academic Press: New York, 1972.
5
6
7

- 8 (57) Akhter, M. S.; Alawi, S. M. The Effect of Organic Additives on Critical Micelle
9
10 Concentration of Non-Aqueous Micellar Solutions. *Colloids Surfaces A*
11
12 *Physicochem. Eng. Asp.* **2000**, *175* (3), 311–320. <https://doi.org/10.1016/S0927->
13
14 7757(00)00671-3.
15
16
17
18
19
20
21
22
23 (58) Ernst, R. R.; Bodenhausen, G.; Wokaun, A. *Principles of Nuclear Magnetic*
24
25 *Resonance in One and Two Dimensions*; Oxford University Press: New York, 1994.
26
27
28
29
30
31 (59) Cockerill, A. F.; Davies, G. L. O.; Harden, R. C.; Rackham, D. M. Lanthanide Shift
32
33 Reagents for Nuclear Magnetic Resonance Spectroscopy. *Chem. Rev.* **1973**, *73*
34
35 (6), 553–588. <https://doi.org/10.1021/cr60286a001>.
36
37
38
39
40
41
42 (60) Wennerström, H.; Lindblom, G. Biological and Model Membranes Studied by
43
44 Nuclear Magnetic Resonance of Spin One Half Nuclei. *Q. Rev. Biophys.* **1977**, *10*
45
46 (1), 67–96.
47
48
49
50
51
52
53
54 (61) Claessens, M. M. A. E.; Van Oort, B. F.; Leermakers, F. A. M.; Hoekstra, F. A.;

1
2
3
4 Stuart, M. A. C. Charged Lipid Vesicles: Effects of Salts on Bending Rigidity,
5
6
7 Stability, and Size. *Biophys. J.* **2004**, *87* (6), 3882–3893.
8
9
10 <https://doi.org/10.1529/biophysj.103.036772>.

11
12
13
14
15 (62) Tatulian, S. A. Effect of Lipid Phase Transition on the Binding of Anions to
16
17
18 Dimyristoylphosphatidylcholine Liposomes. *Biochim. Biophys. Acta* **1983**, *736* (2),
19
20
21
22 189–195. [https://doi.org/10.1016/0005-2736\(83\)90283-3](https://doi.org/10.1016/0005-2736(83)90283-3).

23
24
25
26 (63) Flewelling, R. F.; Hubbell, W. L. The Membrane Dipole Potential in a Total
27
28
29
30 Membrane Potential Model. Applications to Hydrophobic Ion Interactions with
31
32
33
34 Membranes. *Biophys. J.* **1986**, *49* (2), 541–552. [https://doi.org/10.1016/S0006-](https://doi.org/10.1016/S0006-3495(86)83664-5)
35
36
37 3495(86)83664-5.


38
39
40
41 (64) Puckett, C. A.; Ernst, R. J.; Barton, J. K. Exploring the Cellular Accumulation of
42
43
44
45 Metal Complexes. *Dalt. Trans.* **2010**, *39* (5), 1159–1170.
46
47
48
49 <https://doi.org/10.1039/b922209j>.

50
51
52
53 (65) Rokitskaya, T. I.; Sumbatyan, N. V.; Tashlitsky, V. N.; Korshunova, G. A.;

1
2
3
4 Antonenko, Y. N.; Skulachev, V. P. Mitochondria-Targeted Penetrating Cations as
5
6
7 Carriers of Hydrophobic Anions through Lipid Membranes. *Biochim. Biophys. Acta*
8
9
10 - *Biomembr.* **2010**, *1798* (9), 1698–1706.
11
12
13
14 <https://doi.org/10.1016/j.bbamem.2010.05.018>.

15
16
17
18 (66) Petruk, G.; Monti, D. M.; Ferraro, G.; Pica, A.; D'Elia, L.; Pane, F.; Amoresano, A.;
19
20
21
22 Furrer, J.; Kowalski, K.; Merlino, A. Encapsulation of the Dinuclear Trithiolato-
23
24
25 Bridged Arene Ruthenium Complex Diruthenium-1 in an Apoferritin Nanocage:
26
27
28 Structure and Cytotoxicity. *ChemMedChem* **2019**, *14* (5), 594–602.
29
30
31
32 <https://doi.org/10.1002/cmdc.201800805>.

TOC graphic



1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60




Figure 1. Structures of the three diruthenium complexes (1-3) investigated in this work.

165x49mm (600 x 600 DPI)




Figure 2. Superimposed 1D NOE NMR spectra of 1 (1 mM) and DOPC (10 mM) vesicles in PBS/DMSO. Irradiated (a): 1.367 ppm; (b): 3.328 ppm; (c): 7.494 ppm. Mixing time 100 ms, relaxation delay 1s, 2048 scans, 8192 TD data points, acquisition time 511 ms, spectral width 8012.8 Hz.

177x129mm (400 x 400 DPI)




Figure 3. Overlay of DOSY spectra of (a): 1 (1 mM; blue), DOPC (10 mM; red) or mixture of both (green), respectively, dissolved in PBS (50 mM) / DMSO 4:1; (b): 2 (1 mM; blue), DOPC (10 mM; red) or mixture of both (green), respectively, dissolved in PBS (50 mM) / DMSO 4:1.

165x74mm (600 x 600 DPI)




Figure 4. Overlay of DOSY spectra of (a): 1 (1 mM; blue), DOPC (10 mM; red) and 1 codissolved with DOPC upon vesicle formation in PBS (50 mM) / DMSO 4:1 (green); (b): 3 (1 mM; blue), DOPC (10 mM; red) and 3 codissolved with DOPC upon vesicle formation in PBS (50 mM) / DMSO 4:1 (green).

165x74mm (600 x 600 DPI)




Figure 5. Overlay of DOSY spectra of (a): 1 (1 mM; blue), DHPC (28 mM; red) or mixture of both (green), respectively, dissolved in PBS (50 mM) / DMSO 4:1; (b): 2 (1 mM; blue), DHPC (28 mM; red) or mixture of both (green), respectively, dissolved in PBS (50 mM) / DMSO 4:1.

165x75mm (600 x 600 DPI)




Figure 6. T2 relaxation time of (a): 1 (1 mM) protons; (b): 2 (1 mM) protons; (c): 3 (1 mM) protons in the presence of DOPC (10 mM) vesicles or DHPC (28 mM) micelles, respectively, in PBS (50 mM)/DMSO. Only results for resonances with no overlap with phospholipid signals shown. Due to insufficient S/N it was not possible to determine T2 of p-cymene methyl protons in case of 3 in mixture with DHPC.

165x152mm (500 x 500 DPI)




Figure 7. T2 relaxation time of (a): DOPC (10 mM) vesicles or (b): DHPC (28 mM) micelles, respectively, in the presence of 1, 2 and 3, in PBS (50 mM)/DMSO. Only results for resonances with no overlap with signals of the complexes shown.

128x110mm (400 x 400 DPI)




Figure 8. ^{31}P NMR of (a): DOPC (10 mM) vesicles and 1 (1 mM) in presence of 1 mM PrCl_3 in $\text{D}_2\text{O}/\text{DMSO}$, (b): DOPC (10 mM) and 1 (1 mM) in $\text{D}_2\text{O}/\text{DMSO}$, (c): DOPC (10 mM) vesicles and PrCl_3 (1 mM) in $\text{D}_2\text{O}/\text{DMSO}$, (d): DOPC (10 mM) vesicles in $\text{D}_2\text{O}/\text{DMSO}$.

64x96mm (310 x 310 DPI)





Figure 9. ^1H NMR of (a): DOPC (10 mM) vesicles in $\text{D}_2\text{O}/\text{DMSO}$, (b): DOPC (10 mM) vesicles in presence of 1 mM PrCl_3 in $\text{D}_2\text{O}/\text{DMSO}$, (c): DOPC (10 mM) vesicles and 1 (1 mM) in $\text{D}_2\text{O}/\text{DMSO}$, (d): DOPC (10 mM) vesicles, 1 (1 mM) and PrCl_3 (1 mM) in $\text{D}_2\text{O}/\text{DMSO}$.

77x103mm (600 x 600 DPI)



TOC figure

82x40mm (300 x 300 DPI)